161 Azacytidine 75mg/m2 ×5 day in high-risk myelodysplastic syndromes and acute myeloid leukemia refractory/relapsed patients: Results from a single centre

Bergua, Juan; Carmona, María Teresa Padilla; Fernández, José P.; Silva, C. Cabrera; Carnicero, Fernando; Fernandez-Leyva, H.; Miranda, Mirtha; Martín-Mateos, María-Luisa; Izquierdo, F.; Esparraga, E. Gil; Bermejo, Nuria; Blanco, Michelle

doi:10.1016/s0145-2126(11)70163-1

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover only few reports have recently assessed the efficacy and safety of alternative dosing schedules of Azacitidine in MDS and CMML, without compromising the efficacy and the tolerability of the drug compared to the approved schedule. 5 , 8 , 18 – 19 …”

Section: Discussionmentioning

confidence: 99%

“…More patients in the AZA 5 arm completed six cycles of treatment (64%) than in the AZA 5-2-2 (44%) and AZA 5-2-5 (49%). Bergua et al 19 analyzed the results of AZA 5 schedule in patients with high-risk MDS and acute myeloid leukemia refractory to conventional therapy. They concluded that 5 days of therapy seems as effective as 7 days in this unfavourable setting.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Case of Atypical Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (Cmml), Review of Literature and a Proposal of Management

Elli

Cecchetti

Belotti

et al. 2012

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Hypomethylating drugs are useful and have been approved for the treatment of myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). However, phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of patients with CMML, and there are just a few specific reports on CMML patients. The Azacitidine is actually authorised for the treatment of CMML patients with 10–29% marrow blasts without myeloproliferative disorder, who are not eligible for haematopoietic stem cell transplantation. This hypomethylating agent in MDS is known for causing transient cytopenias, most often occurring during the first 2 cycles. Here we report a case of an atypical delayed and prolonged hematologic toxicity during Azacitidine treatment in a CMML patient; furthermore we also reviewed the literature regarding the efficacy of the drug and the management of hematologic adverse effects, in term of dose adjustments or alternative schedule of administration, in specific CMML setting.

show abstract